1.24
6.06%
-0.08
Nektar Therapeutics stock is currently priced at $1.24, with a 24-hour trading volume of 4.72M.
It has seen a -6.06% decreased in the last 24 hours and a +42.82% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.32 pivot point. If it approaches the $1.23 support level, significant changes may occur.
Nektar Therapeutics Stock (NKTR) Financials Data
Nektar Therapeutics (NKTR) Revenue 2024
NKTR reported a revenue (TTM) of $90.12 million for the quarter ending December 31, 2023, a -2.10% decline year-over-year.
Nektar Therapeutics (NKTR) Net Income 2024
NKTR net income (TTM) was -$276.06 million for the quarter ending December 31, 2023, a +25.03% increase year-over-year.
Nektar Therapeutics (NKTR) Cash Flow 2024
NKTR recorded a free cash flow (TTM) of -$193.47 million for the quarter ending December 31, 2023, a +37.53% increase year-over-year.
Nektar Therapeutics (NKTR) Earnings per Share 2024
NKTR earnings per share (TTM) was -$1.46 for the quarter ending December 31, 2023, a +25.89% growth year-over-year.
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
Seeking Alpha
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
Zacks Investment Research
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
Zacks Investment Research
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Zacks Investment Research
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Cap:
|
Volume (24h):